Your browser doesn't support javascript.
loading
Lentiviral-based approach for the validation of cancer therapeutic targets in vivo.
Ambrogio, Chiara; Stern, Patrick; Scuoppo, Claudio; Kranz, Harald; Barbacid, Mariano; Santamaría, David.
Affiliation
  • Ambrogio C; Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Spanish National Cancer Research Center, Madrid, Spain.
  • Stern P; Sextant Therapeutics Inc, Cambridge, MA and Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA.
  • Scuoppo C; Institute for Cancer Genetics and Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York.
  • Kranz H; Gene Bridges, GmbH Commercial Centre, Heidelberg, Germany.
  • Barbacid M; Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Spanish National Cancer Research Center, Madrid, Spain.
  • Santamaría D; Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Spanish National Cancer Research Center, Madrid, Spain.
Biotechniques ; 57(4): 179, 181-7, 2014 Oct.
Article in En | MEDLINE | ID: mdl-25312087
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lentivirus / Neoplasms Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Biotechniques Year: 2014 Type: Article Affiliation country: Spain
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lentivirus / Neoplasms Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Biotechniques Year: 2014 Type: Article Affiliation country: Spain